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21 Abstract
2 Nowadays, drug pollution; a form of water pollution caused by some pharmaceuticals 
3 and their metabolites resulting from consumers, industry and hospitals was reported. 
4 Colchicine (CLN) is considered one of the pharmaceutical wastewater contaminants 
5 which are not eliminated completely in municipal sewage treatment plants and are 
6 discharged into receiving water. Due to the higher toxicity of CLN, a novel 
7 heterogeneous Fenton's-like catalysis was established for complete degradation of 
8 CLN. So, a highly sensitive and specific liquid chromatographic method with 
9 quadrupole mass spectrometry (LC/Q-MS) was developed and validated for 
10 estimation of CLN in its pure form and in the presence of its degradation product. 
11 Herein, GraceSmart RP C18 column was utilized for separation of the cited drug 
12 (Retention time tR= 5.578 min) using methanol: water (55: 45, v/v) at 1.0 mL/min. 
13 Detection was performed by Agilent 6120 Quadrupole MS detector in a positive 
14 ionization mode. 
15 Thereafter and for the first time, degradation of CLN by heterogeneous Fenton's-like 
16 catalysis using modified polyacrylonitrile (PAN) as a catalyst with H2O2 in aqueous 
17 acidic medium was performed. This process was firstly optimized by HPLC/UV 
18 detection at 248 nm using the aforementioned chromatographic conditions. As a 
19 result, CLN degraded completely within 30 min. The only observed degradation 
20 product was the biologically active, potent and less toxic antitumor metabolite of 
21 CLN (3- demethyl CLN) which was collected, extracted, and analyzed by Fourier 
22 Transfer- Infrared Spectroscopy (FTIR) and 13Carbon- Nuclear Magnetic Resonance 
23 (13C-NMR).  
24 Finally, this method is eco-friendly and complies with the requirements of the green 
25 chemistry. It is suitable for complete removal of CLN and/or its metabolite 
26 contaminants from wastewater samples and estimation of the target drug without any 
31 interference from its degradation products. However, further study is required to 
2 expand the method applicability to the pharmaceutical wastewater treatment as well 
3 the production of 3- demethyl CLN on a large scale.
4 Keywords
5 Colchicine; 3- demethyl colchicine; Liquid chromatography-mass spectrometry; 
6 Fenton's-like catalysis; Drug pollution. 
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41 1. Introduction
2 Nowadays, drug pollution; a form of water pollution caused by some pharmaceuticals 
3 and their metabolites resulting from consumers, industry and hospitals was reported. 
4 Pharmaceutical pollutants are not eliminated completely in municipal sewage 
5 treatment plants and are discharged into receiving water [1-4]. Drug pollution comes 
6 simply from the excreted drugs and/or their metabolites in the urine in addition to the 
7 expired or unneeded drugs that are flushed unused down the toilet [3]. Other sources 
8 of such pollution include agricultural runoff (because of antibiotic use in livestock) 
9 and pharmaceutical manufacturing [1, 3].
10 Filtration to remove course solids followed by biological treatment and sand filtration 
11 are the common processes used for wastewater treatment. Also, Fenton's reagent 
12 (H2O2 with Fe2+ as a catalyst) a form of Advanced Oxidation Process (AOP) is widely 
13 utilized to oxidize organic water pollutants to carbon dioxide and water by a powerful 
14 hydroxyl radical as following [3, 5];
15 OH (Hydroxyl radical) + OH−  Fe2+ + H2O2 → Fe3+ + 
16 OOH (Hydroperoxyl radical) + H+  Fe3+ + H2O2 → Fe2+ + 
17 OH → Oxidation products R (organic substance) + 
18 But the main limitations of classical Fenton's oxidation are pH modulation, the 
19 presence of the catalyst in the final treated samples and the production of sludge 
20 formed by the precipitation of Iron (III) oxo/hydoxo species which are insoluble at the 
21 pH of the process. This sludge is also likely to be contaminated by non-degraded 
22 pollutant [6].
23 To overcome these demerits, a heterogeneous form of the classical Fenton's catalyst 
24 incorporating Fe3+ cations in a Fenton's- like catalysis was designed by using 
25 modified polyacrylonitrile (PAN) fibres [7-8]. This modification process involves the 
26 impregnation of catalytically active transition metal complexes on the functionalized 
51 surface of PAN fibres. Transition metals are preferred because of their partially filled 
2 d orbitals making them highly reactive [9]. Studies at De Montfort University has led 
3 to further development of a novel PAN catalyst through the immobilization of Fe3+ on 
4 the surface of the PAN. The presence of chemically highly reactive nitrile groups on 
5 the polymer allowed functionalization with a mixture of hydroxylamine and hydrazine 
6 salts in alkaline solution to form chelating ligands (carboxylate, amides and oxime) 
7 [8, 10]. This indigenous catalyst has been successfully tested for the oxidative 
8 decomposition of several waste effluents from pharmaceutical, textile, agrochemical, 
9 and other model compounds at laboratory scale in a heterogeneous Fenton-like 
10 process using H2O2 as an oxidant in a similar cyclic redox mechanism to the 
11 aforementioned where the produced hydroxyl radical reacts with the organic pollutant 
12 to form oxidation products [11-12].
13 Colchicine (CLN) is considered one of the pharmaceutical wastewater contaminants 
14 [1, 2, 13]. CLN is an alkaloid obtained from different Colchicum species (Figure 1). It 
15 is an official drug in the European, Chinese, Japanese, and International 
16 Pharmacopeias as well USP. It is commonly used to relieve pain and inflammation 
17 associated with acute gouty attacks by decreasing the leucocyte mobility [14]. CLN 
18 also has an antimitotic action and is widely used in treatment of amyloidosis, Behçet’s 
19 syndrome, familial Mediterranean fever, idiopathic thrombocytopenic purpura, 
20 pericarditis, primary biliary cirrhosis, and pyoderma gangrenosum [15]. Nausea, 
21 diarrhea, vomiting and abdominal pain associated with CLN antimitotic action are its 
22 main side effects and the first signs of its toxicity. With CLN overdose; anemia, 
23 multiple organ failure, bone marrow depression, hepatocellular with muscle damage, 
24 renal damage and CNS toxicity have been reported [13-15]. 
61 Furthermore, CLN derivatives such as 3-demethyl CLN (Figure 1), 2-demethyl CLN, 
2 colchicoside and thiocolchicoside have been reported for their possible application in 
3 management of certain forms of leukemia and solid tumors [16]. Unlike CLN, they 
4 have potent anti-inflammatory and anti-tumor activity with lower toxicity. But, due to 
5 rarity of CLN derivatives through CLN-producing plants, many trials have been made 
6 to find alternative routes for their industrial-scale production [16-19]. 
7 Biotransformation of CLN employing CYP3A4 enzyme or microbial demethylation 
8 were reported for CLN demethylation [17-19].
9 Concerning literature, liquid chromatography (with UV, MS or Tandem MS 
10 detection) [20-28], gas chromatography [29-30], thin layer chromatography (TLC) 
11 [31-33], fluorimetric and spectrophotometric methods [34-37] have been reported for 
12 estimation of CLN alone or combined with other drugs.
13 The present work is the first study that focuses on the application of heterogeneous 
14 Fenton's-like catalysis for fully degradation of CLN using the modified PAN catalyst 
15 with H2O2 in aqueous acidic medium. So, a highly sensitive and specific liquid 
16 chromatographic method with quadrupole mass spectrometry (LC/Q-MS) for 
17 estimation of CLN in pure form and in the presence of its degradation product was 
18 developed and validated. 
19 Thereafter, the biologically active, potent and less toxic antitumor derivative of CLN 
20 (3- demethyl CLN) produced during CLN degradation was collected, extracted, and 
21 analyzed by Fourier Transfer- Infrared Spectroscopy (FTIR) and 13Carbon- Nuclear 
22 Magnetic Resonance (13C-NMR). 
23 This work was designed to fulfill the principles required for the green chemistry [38]. 
24 So, hazards from chemical toxicity and waste reduction in addition to discovering 
25 replacements for hazardous substances were our main targets.
71 2. Experimental
2 2.1. Apparatus
3 Agilent 6120 Quadrupole LC/MS system linked to 1260 Infinity auto-sampler, 
4 solvent manager, pump, thermostated column chamber and Quadrupole MS detector 
5 (Agilent Technologies, USA) was used. This system was operated with OpenLAB 
6 CDS ChemStation Edition C. 01. 06 software. PerkinElmer Series 200 HPLC System 
7 (Model LCTURBO, Serial no. ZAAA0646, PerkinElmer® Inc., USA) connected to 
8 series 200 degasser, pump and UV/VIS detector was utilized for optimization of the 
9 drug degradation process. A rheodyne injection valve (Model 7725i, USA) with a 20 
10 μL loop and 100 μL Hamilton – Bonaduz, Schweiz (Switzerland) sample syringe 
11 were used for sample application. The HPLC system was operated with TotalChrom 
12 Workstation version 6.3.4 software. The GraceSmart RP C18 encapped column (250 
13 mm length x 4.6 mm inner diameter, 5 µm particle size, 120 Å pore size) was coupled 
14 to either LC/MS or HPLC/UV system.
15 ALPHA FTIR (Serial no. GI004911, operated with OPUS Spectroscopy Software) 
16 and AVANCETM- UltraShield 400 NMR (Serial no. GH007300) spectrometers 
17 (BRUKER UK Limited, UK) in addition to Thermo Scientific-Evolution 220 UV-VIS 
18 spectrophotometer with 1 cm quartz cuvettes (Waltham, Massachusetts, USA) were 
19 also used. Moreover, analytical series Fisher-Scientific balance-PAS214C (China), 
20 Jenway 350 pH meter (China) and ultrasonic cleaner- Kerry PUL 125 (England) were 
21 utilized. Furthermore, Nylon 66 membranes (0.45 µm pore size, 47.0 mm diameter) 
22 and Fisherbrand PTFE syringe filters (0.45 µm) were obtained from SUPELCO, USA 
23 and Fisher Scientific Co., UK; respectively.
81 Regarding the catalytic oxidation process, Carousel 6 Plus Reaction Station™ set 
2 (Radleys, UK) consists of stirring hotplate and 250 mL-round bottom flasks with 
3 reflux head was used.
4 Interflon glass gravity column (200 mm length x 20 mm inner diameter, Sigma-
5 Aldrich Co., UK) and UVGL-55 Handheld lamp (USA) were utilized during 
6 extraction of the degradation product. Also, Quantofix® peroxide semi-quantitative 
7 test strips (Macherey-Nagel Germany) and Büchi Rotavapor R-300 (UK) were used.
8 2.2. Chemicals and Solvents
9 CLN (≥95%) was purchased from Sigma-Aldrich Co., UK. LC/MS grade methanol 
10 (99.95%) and water (99.9%) were purchased STRATLAB Laboratory Supplies, UK. 
11 HPLC grade Hydrogen peroxide (30% w/w), analytical grade hydrochloric acid 
12 (36%), sodium hydroxide, FeSO4.7H2O and Acros OrganicTM deuterated chloroform 
13 for NMR were bought from Fisher Scientific Co., UK.
14 Modified PAN catalytic mesh was supplied by School of Pharmacy, De Montfort 
15 University, Leicester, UK.
16 TLC aluminium sheets precoated with silica gel G 60F254 plates (Fluka, 5 x 5 cm, 0.20 
17 mm layer thickness) and Silica gel for column chromatography (200-400 mesh, 60 Å) 
18 were obtained from Sigma-Aldrich Co., UK. 
19 2.3. Standard Solutions preparation.
20 50.0 mg of CLN were dissolved in 50.0 mL water to obtain the stock standard 
21 solution (1.0 mg mL-1). This solution was kept in a refrigerator away from light. 
22 The stock solution was firstly diluted with water to prepare 200 ng mL-1 followed by 
23 serial dilution with the same solvent to prepare the working standard solutions (0.1-50 
24 ng mL-1).
25
91 2.4. Analytical procedures.
2 2.4.1. General Chromatographic Conditions.
3 10 µL of the working standard or sample solution of the studied drug was injected 
4 automatically by the autosampler on Agilent 6120 Quadrupole LC/MS system linked 
5 to GraceSmart RP C18 column (250 mm length x 4.6 mm inner diameter, 5 µm 
6 particle size, 120 Å pore size; Controlled temperature at 25± 0.8°C). Then, isocratic 
7 elution was carried out by methanol: water (55:45, v/v) at flow rate 1.0 mL min-1. The 
8 total run time was 10 minutes.
9 Detection was performed by Agilent 6120 Quadrupole MS detector in a positive 
10 ionization mode (Drying gas: N2 at 12.0 L/min;  its Temp. 350°C, Capillary voltage 
11 3000 V, and the main settings: Rough Vacuum 1.38 Torr, Quadrupole Temp. 100°C, 
12 Nebulizing Pressure 35 psig, TurboSpd 100%, Fragmentor 70, Gain 1.0, Threshold 
13 150). MS data were collected as either total ion current (TIC, m/z 50-500), or selected 
14 ion monitoring (SIM) at m/z 400.4. CLN mass spectrum showed a prominent 
15 molecular ion [M+H]+ peak at m/z= 400.2.
16 2.4.2 Construction of Calibration Curves.
17 Working standard solutions of CLN equivalent to (0.10, 1.0, 10.0, 20.0, 30.0, 40.0 and 
18 50.0 ng mL-1) were prepared in water. Then, the assay was done as mentioned under 
19 the general chromatographic conditions (Section 2.4.1). 
20 The peak area values (µV*Sec) were plotted against the drug final concentration (ng 
21 mL-1) to get the calibration graph. Thereafter, the corresponding regression equation 
22 was calculated.
23
24
25
10
1 2.5. Degradation of Colchicine.
2 2.5.1. Preparation of PAN Catalyst.
3 To remove excess iron from the PAN catalyst, washing of the mesh was performed by 
4 scrubbing and immersing it in tap water. The colour of water changed from clear to 
5 brown which shows leaching off the excess iron from the surface of the catalyst. This 
6 process was done until there was no further colouration. The washed PAN was cut to 
7 pieces (20*20 cm) and transferred into a beaker with double distilled water then pH 
8 was adjusted at 3.0 using 0.1 N hydrochloric acid and/or sodium hydroxide. Upon 
9 stabilization of pH (3.0), the PAN mesh was removed away from water and air-dried 
10 at room temperature.
11 2.5.2. Procedure for CLN Degradation.
12 Working standard solution of CLN (50.0 µg mL-1) was prepared in acidic double 
13 distilled water (pH 3.0; adjusted by 0.1 N HCl and/or NaOH). 100 mL of this working 
14 solution were transferred into a carousel flask followed by addition of 8 grams of 
15 PAN catalyst (cut into 2 cm2 pieces) and a magnetic stirrer flea. pH of the flask 
16 content was checked and readjusted to the desired value (3.0). Carousel 6 Plus 
17 Reaction Station™ stirring hotplate was set to 500 rpm at 25°C to ensure a proper 
18 mixing (Figure S1). Thereafter, the catalytic reaction was initiated by addition of 100 
19 µL of 30% H2O2 (corresponding to 333 ppm) to the flask content (CLN+ PAN). 
20 Samples were taken at predetermined time intervals of 5 min to monitor the 
21 degradation of CLN (the targeted drug degraded completely within 30 min). The first 
22 sample (0 min; CLN only) was taken before the introduction of the catalyst. 
23 Subsequently, the catalyst and H2O2 were added and the samples were pulled every 5 
24 min and filtered through PTFE syringe filters. 10 µL of the collected samples were 
25 then injected on LC/MS system. The assay was then carried out in triplicates as 
11
1 mentioned before (Section 2.4.1). MS data were collected as either TIC at m/z 50-500 
2 or SIM at m/z 400.4 and 386.4 for CLN and its degradation product; respectively. 
3 Mass spectra showed two prominent molecular ion peaks [M+H]+ at m/z= 400.2 and 
4 386.1 for CLN and demethylated-CLN; respectively..
5 Blank experiment was done in the same manner excluding the drug.  
6 Furthermore, two experiments were performed similarly to evaluate the CLN stability 
7 in the absence of the PAN catalyst (The first was for CLN in acidic water; while the 
8 second one was for CLN in presence of H2O2 at pH 3.0).
9 2.5.3. Isolation of the degradation product.
10 During the degradation process, CLN degraded to its biologically active, potent and 
11 less toxic antitumor metabolite (3- demethyl CLN). It reached a maximum 
12 concentration within 5 min of the catalytic oxidation reaction. Due to the product 
13 medical importance, we tried to separate and collect it by the aid of TLC and 
14 fractional column chromatographic techniques.
15 The catalytic oxidation reaction was stopped after 5 min via the removal of PAN 
16 pieces (by filtration) and evaporation of excess H2O2 (by heating on a water bath for 5 
17 min and H2O2 content was checked by Quantofix® peroxide semi-quantitative test 
18 strips). The degraded solution mixture (CLN and its metabolite) was preliminary 
19 separated on silica gel TLC plates using methanol: water (55:45, v/v) and the spots 
20 were visualized by portable UV- lamp at 254 nm (Retardation factor (Rf) = 0.61 and 
21 0.13 for CLN and its derivative; respectively).
22 Subsequently, the fractional column chromatographic method was established to 
23 collect each compound separately. Interflon glass column (200 mm length x 20 mm 
24 inner diameter) was carefully packed with silica gel and conditioned by methanol then 
25 loaded with the degraded solution mixture. Methanol: water (55:45, v/v) was firstly 
12
1 used as a mobile phase to elute CLN. Then, 3- demethyl CLN was eluted by 100% 
2 water. The eluted fractions were checked for their purity by TLC plates and UV/VIS 
3 spectrophotometer (Figure S2).
4 The collected fractions of 3- demethyl CLN were evaporated using Büchi Rotavapor 
5 R-300 to obtain a yellowish- white powder of the desired product. 
6 For structure confirmation, CLN and 3- demethyl CLN samples were analyzed by 
7 FTIR and NMR spectrometers.
8 3. Results and Discussion
9 The main objective of the presented work is to establish an eco-friendly method for 
10 fully degradation of CLN by heterogeneous Fenton's-like catalysis for the first time 
11 (using modified PAN catalyst with H2O2 in aqueous acidic medium). So, a simple, 
12 highly sensitive and specific LC/Q-MS method was developed and validated for 
13 determination of CLN in its pure form and in the presence of its degradation product.
14 Finally, the isolation and identification of the biologically active metabolite of CLN 
15 (3- demethyl CLN) produced during the degradation process were achieved. 
16 3.1. The developed LC/Q-MS Method.
17 3.1.1. Chromatographic Conditions Optimization.
18 To achieve a good resolution and fast analysis with symmetric peaks, mobile phase 
19 composition and flow rate were tested.
20 3.1.1.1. Mobile phase
21 After testing acetonitrile, methanol and ethanol as organic solvents, a good resolution 
22 and a sharp peak with higher area was observed when methanol was the organic 
23 modifier. While, ethanol and acetonitrile gave asymmetric peak with CLN (broad and 
24 tailed). Also, the percentage of the chosen organic solvent was varied (from 10 % to 
25 90 %). Upon increasing the methanol percentage ≥70%, improper resolution between 
13
1 CLN and its degredant was observed. On the other hand, good separation was 
2 achieved within longer run time (>10 min) when the methanol content was decreased 
3 ≤40%.  So, the chosen mobile phase (55% methanol to 45% water) gave the best 
4 resolution and sharp peak of the target drug in presence of its degradation product 
5 within reasonable time (6 min). The retention times (tR) were 5.578 and 4.281 for 
6 CLN and 3-demethyl CLN; respectively. The LC/MS chromatograms for the cited 
7 drug and its degradation product were shown in Figure 2.
8 3.1.1.2. Flow rate
9 The influence of flow rate on the separation of CLN alone or in presence of its 
10 degradation product was studied in the range of 0.3-2 mL min-1. In the preliminary 
11 studies, overlapping and poor resolution was observed at higher flow rates ≥1.2. But 
12 at lower flow rates ≤0.8, good resolution was achieved with broad asymmetric peaks 
13 at longer run time (more than 10 min) for the entire elution of these compounds. So, 
14 an isocratic mode of flow rate (1 mL min-1) was set to enhance the method's 
15 resolution within short separation time (less than 6 min). Thus, the proposed method 
16 can successfully applied for rapid analysis of CLN in the presence of its degredant.
17 3.1.2. Method Validation.
18 As mentioned in ICH guidelines on the validation of analytical methods ICH Q2 (R1), 
19 linearity, detection (LOD) and quantification (LOQ) limits, precision, accuracy, 
20 robustness, selectivity and specificity of the proposed LC/MS were evaluated [39]. 
21 3.1.2.1. Linearity and sensitivity parameters.
22 According to the optimal chromatographic conditions, six calibration curves for 
23 standard solutions of CLN at seven concentration levels (Figure 3) were constructed 
24 by plotting peak area against drug concentration (ng mL-1). The results presented in 
14
1 Table 1 indicate good linearity over a range of 0.10 – 50.0 ng mL-1 with an excellent 
2 correlation coefficient (0.9999). 
3 Also, 3 σ/S and 10 σ/S were used for calculation of LOD and LOQ of the studied 
4 drugs; respectively (σ is the standard deviation of y-intercept of the regression 
5 equation and S is the slope of the calibration curve). The lower LOD and LOQ values 
6 obtained (16.4 and 49.8 pg mL-1; respectively) indicate a high sensitivity of the 
7 proposed method. In conclusion, the method's simplicity and sensitivity are superior 
8 to other reported LC/MS or Tandem MS methods [23-28].
9 3.1.2.2. Accuracy and precision
10 Low, medium, and high concentration ranges (0.100, 20.0, and 50.0 ng mL-1) of CLN 
11 were analyzed by the developed LC/MS method. After injection of each 
12 concentration in six replicates, recovery percentages were calculated. The recoveries 
13 were in the range from 100.12 to 100.18% with RSD ≤0.89% indicating good 
14 accuracy of the proposed method (Table 2). Moreover, the three above-mentioned 
15 concentrations were analyzed in triplicates for intra-day precision and gave recoveries 
16 of (99.90-100.34%) and (99.67-100.36%) for inter-day precision (n= 9). RSD values 
17 were found to be ≤ 0.68 for intra- and inter-day precision (Table 2). These results 
18 confirm that the acceptable repeatability and accuracy of the proposed method for 
19 assay of CLN.
20 3.1.2.3. Robustness. 
21 Minor changes of the optimal chromatographic parameters were studied.  It was found 
22 that the slight alteration in flow rate and mobile system composition had no 
23 significant influence on the method's performance. The results shown in Table 3 
24 indicate the reliability of our method during normal usage.
25 3.1.2.4. Specificity and selectivity.
15
1 The proposed method is able to separate the studied drug completely from its 
2 degradation product. After injection of the obtained degraded solution (CLN with its 
3 derivative), clean chromatograms were observed without any interfering peaks from 
4 the catalyst, H2O2 or the degradation product especially at the target retention time 
5 (Figure 2 & 4). Additionally, the method's specificity was enhanced using MS 
6 detection with SIM at the drug's m/z 400.4.
7 3.2. Optimization of CLN Degradation Reaction.
8 To ensure a complete and efficient degradation process, reaction parameters (PAN 
9 catalyst amount, H2O2 volume and the effect of pH) were evaluated using HPLC/UV 
10 system. 
11 The procedure of CLN degradation (section 2.5.2) was carried out and the samples 
12 were pulled after 15 min of the reaction time. 20 µL of the sample was then injected 
13 manually on HPLC/UV system. As mentioned before (section 3.1.1), methanol: water 
14 (55: 45, v/v) at flow rate (1.0 mL min-1) were used as the optimal chromatographic 
15 conditions during this study. The UV detector was set at 248 nm (One of two 
16 maximum wavelengths of CLN; Figure S3).
17 Figure 4 represents the HPLC - Chromatograms of CLN with and without its 
18 degradation product.
19 3.2.1. PAN Catalyst Amount
20 The procedure for CLN degradation (section 2.5.2) was performed using different 
21 weights of PAN mesh (2, 4, 6, 8, 10 g). It was found that 8 g of PAN catalyst gave the 
22 lowest peak area of CLN and an efficient degradation (Figure 5A).
23 3.2.2. Volume of H2O2 
24 To study the effect of H2O2 concentration on the degradation reaction, different 
25 volumes (20, 40, 60, 80, 100, 120, 140 µL) of 30% H2O2 were evaluated. As shown in 
16
1 (Figure 5B), the highest amount of CLN (about 92 %) was degraded within 15 min 
2 upon using 100 µL of 30% H2O2 (=333 ppm). 
3 On the other hand, calibration curve of H2O2 was constructed by plotting peak areas 
4 against different concentrations of H2O2 (50- 400 ppm) in acidic water (pH 3.0). The 
5 obtained linear regression equation was Y= 6088.4 X + 106; R² = 0.9945 (Figure S4). 
6 We found that ~ 85% of the chosen initial concentration of 30% H2O2 (100 µL) was 
7 consumed on CLN complete degradation. Also, H2O2 scavenges hydroxyl radical 
8 upon the increase of H2O2 concentration.
9 3.2.3. Effect of pH
10 Variation of pH of both CLN working standard solution and PAN mesh (during its 
11 preparation) was investigated. Chu et al. [40] found that the oxidation potential of 
12 hydroxyl radicals decreased with increasing pH. Also, degradation rate and efficiency 
13 decreased at pH below 3.0 due to the formation of iron complex species [Fe(H2O)6]2+ 
14 which reacts more slowly with H2O2 [41].  While; at slightly higher pH >3.0, the 
15 activity of Fenton's reagent was reduced due to the presence of an inactive iron 
16 oxohydroxides [42]. So, different low pH values (3.0, 3.5, 4.0, 4.5; adjusted by 0.1 N 
17 HCl and/or NaOH) were tested.  A higher loss of CLN content was achieved at pH 3.0 
18 (Figure 5C). Our finding agrees with many previous studies that recommended the 
19 use of pH 3.0 for Fenton’s oxidation [4].
20 3.2.4. Monitoring of Degradation Reaction.
21 To monitor the degradation of CLN, the samples were analyzed by LC/Q-MS under 
22 the optimal reaction parameters at different reaction time (time intervals of 5 min over 
23 0- 30 min). MS data were collected as either total ion current (TIC, m/z 50-500), or 
24 selected ion monitoring (SIM) at m/z 400.4 and 386.4 for CLN and its demethylated 
25 product; respectively). As a result, CLN was completely degraded within 30 min 
17
1 (Table S1). One product was observed during this reaction (3- demethyl CLN; tR= 
2 4.281 min; m/z 386.1).  Its highest concentration was reached within 5 min of the 
3 reaction time.
4 At 30 min of the reaction time, neither CLN nor its product's peaks were detected 
5 (Figure 6). As a result, this method could be applied successfully for the complete 
6 removal of CLN and/or its derivative from the wastewater during the treatment 
7 process.  
8 3.3. Isolation and Identification of the Degradation Product. 
9 Due to the medical importance of the resulting compound (3- demethyl CLN) during 
10 the CLN catalytic oxidation process, we tried to extract and identify it. 3- Demethyl 
11 CLN is more polar than CLN. So, it was separated easily with a simple fractional 
12 column chromatographic technique. Thereafter, its collected dried fractions were 
13 characterized by ALPHA FTIR and AVANCETM- UltraShield 400 NMR 
14 spectrometers in addition to Thermo Scientific-Evolution 220 UV-VIS 
15 spectrophotometer. The UV spectra (Figure 7A& A') showed a slight blue shift of 3- 
16 demethyl CLN (343 nm) compared to CLN (350 nm) because of the demethylation of 
17 CLN. Furthermore, MS spectrum (Figure 2) showed a signal at m/z 386.1 
18 corresponding to 3- demethyl CLN. For further structure elucidation, a signal of 
19 phenolic hydroxyl group (3657 cm -1) was detected on FTIR spectrum of 3- demethyl 
20 CLN (Figure 7B'). Also, 13C-NMR spectrum of 3- demethyl CLN (Figure 7C') 
21 confirmed that the absence of methoxy group signal at position 3 (56.42 ppm) as 
22 compared with the standard CLN spectrum (Figure 7C). Our 13C-NMR data of CLN 
23 and 3- demethyl CLN that agree with Dubey et al. and Zhang et al. findings [16, 19] 
24 are summarized in Table S2. Our results ensured that hydroxyl radical (produced from 
25 Fenton's- like catalysis) attacks CLN at position no. 3 and not the other positions. 
18
1 Methoxy group is an electron-donating making the attached carbons more attractive to 
2 the electron-seeking hydroxyl radical. Attack at C-3 is preferred over attack at C-1 or 
3 C-2 as these sites are sterically hindered [43].
4 3.4. Stability of CLN.
5 To evaluate the CLN stability in the absence of PAN catalyst; influence of 100 µL of 
6 H2O2 and/or acidic aqueous medium (pH 3.0; adjusted by 0.1 N HCl) on CLN (50.0 
7 µg/mL) were studied using HPLC/UV detection. It was observed that the cited drug 
8 was stable in H2O2 and/or acidic medium for at least 30 min without any detected 
9 degradation (Figure 8). On the other hand, CLN disappeared within 30 min in the 
10 presence of PAN catalyst with H2O2 at pH 3.0 (Figure 6). 
11 4. Conclusion.
12 Eco-friendly, highly sensitive and specific liquid chromatographic method with 
13 quadrupole mass spectrometry (LC/Q-MS) was developed and validated for 
14 quantitation of colchicine (CLN) in its pure form and in the presence of its 
15 degradation product. MS data were collected as either total ion current (TIC, m/z 50-
16 500), or selected ion monitoring (SIM) at m/z 400.4 for CLN. A good linearity 
17 (r=0.9999) was achieved over a concentration ranging from 0.1 to 50 ng/mL with 
18 LOD (16.4 pg//mL). 
19 Additionally and for the first time, heterogeneous Fenton's-like catalysis was 
20 established for degradation of CLN using modified polyacrylonitrile (PAN) catalyst 
21 with H2O2 at pH 3.0. As a result, CLN degraded completely within 30 min. 
22 Thereafter, the biologically active, potent and less toxic antitumor metabolite of CLN 
23 (3- demethyl CLN) produced during CLN degradation was collected, extracted, and 
24 analyzed by Fourier Transfer- Infrared Spectroscopy (FTIR) and 13Carbon- Nuclear 
25 Magnetic Resonance (13C-NMR).  
19
1 Finally, this work is the first study developed for complete removal of CLN from the 
2 water samples and production of less toxic and expensive antitumor drug (3- demethyl 
3 CLN). This work has important environmental and pharmaceutical impact to 
4 wastewater treatment from pharmaceutical pollutants as well the production of an 
5 expensive antitumor drug at the same time. It also complies with the requirements of 
6 green chemistry.
7 However, further study is required to expand the method applicability on the 
8 pharmaceutical wastewater treatment as well the large scale production of 3- 
9 demethyl CLN.
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1 Figure captions
2 Figure 1. Chemical structures of the investigated drug and its derivative.
3 Figure 2. Total ion current (TIC) chromatograms and mass spectra of CLN (A & A') 
4 and its degradation product (B & B').
5 Figure 3.  Three dimensional diagram of LC/MS Chromatograms of CLN in seven 
6 concentration levels (0.10 – 50.0 ng mL-1); three replicates for each concentration.
7 Figure 4. HPLC - Chromatograms of (A) standard solution of CLN (50.0 g mL-1), 
8 (B) CLN with its degradation product (after 5 min of the reaction time), (C) 1.0 
9 mg/mL FeSO4.7H2O solution, (D) PAN catalyst and (E) PAN catalyst with H2O2; all 
10 solutions were prepared at pH 3.
11 Figure 5. Effects of (A) PAN catalyst amount, (B) the volume of 30% H2O2 and  (C) 
12 pH on the degradation of CLN (50.0 g mL-1) (Samples were measured after 15 min 
13 of the reaction time).
14 Figure 6. Influence of the reaction time (0-30 min) on CLN (50.0 g mL-1) 
15 degradation. 
16 Figure 7. Structure elucidation of CLN (A, B & C) and 3- demethyl CLN (A', B' & 
17 C') using UV, FTIR and 13C-NMR; respectively. 
18 Figure 8. The stability of 50.0 µg mL-1 CLN in the presence of 100 µL of 30% H2O2 
19 and/or acidic aqueous medium (pH 3.0); with/without PAN catalyst.
20
21
22
23
24
25
27
1 Table 1. Optimum chromatographic conditions and quantitative parameters of the 
2 proposed LC/MS method for determination of CLN.
Studied drug CLN
Mobile phase Methanol: Water (55: 45, v/v)
Retention time; tR (min) 5.578
Linearity range (ng mL-1) 0.1 – 50
Correlation coefficient (r) 0.9999 
Determination coefficient (R2) 0.9997 
Intercept (a) ± SDa 1.50×105 ± 728.97
Slope (b) ± SDa 1.46×105 ± 89.27
LODb 16.4
LOQc 49.8
3 aAverage of six replicates.                           
4 bLimit of detection (pg mL-1).                                     
5 cLimit of quantitation (pg mL-1).
6
7
8
9
10
11
12
13
14
28
1 Table 2. Accuracy, Intra-day and Inter-day precision of the developed LC/MS method for 
2 determination of CLN.
Authentic 
drug
Concentration 
(ng mL-1)
Accuracy Intra-day precision Inter-day precision
% Recovery 
 SD*
RSD % % Recovery 
 SD**
RSD % % Recovery 
 SD***
RSD %
CLN
0.10
20.0
50.0
100.15 ± 0.84
100.18 ± 0.67
100.12 ± 0.89
0.84
0.67
0.89
100.34  0.62
99.90  0.34
100.24  0.12
0.62
0.34
0.12
100.36  0.68
100.29  0.40
99.67  0.22
0.68
0.40
0.22
3 * Average of six replicates.
4 **Average of three replicates.
5 ***Average of nine replicates.
6 - Results are calculated from standard curve.
7
8
9
10
11
12
13
14
15
16
17
29
1 Table 3. Robustness of the developed LC/MS method for determination of CLN.
Parameter % Recovery  SD* RSD %
No variation** 100.25 ± 0.77 0.77
Methanol: Water ;           58:42, v/v
                                           52:48, v/v
100.50 ± 0.71
99.45 ± 0.96
0.70
0.96
Flow rate;                   +0.1 mL/min
                                    -0.1 mL/min
101.21 ± 1.18
100.56 ± 0.49
1.17
0.48
Column temperature;             27°C 
23°C
100.51 ± 0.51
99.68 ± 0.42
0.51
0.42
2 * Average of three replicates.
3 ** No variation in the chromatographic conditions of the proposed method. The 
4 optimized conditions were [GraceSmart RP C18 column using methanol: water (55: 
5 45, v/v) at 1.0 mL/min, Quadrupole MS detector in a positive ionization mode at total 
6 ion current (TIC, m/z 50-500), or selected ion monitoring (SIM, m/z 400.4)].  (Drug 
7 conc. = 20.0 ng mL-1).
8
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10
11
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Table S1. Monitoring of the degradation of colchicine by the developed LC/MS 
method. 
*Average of three replicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
± Standard Deviation 
(± SD) 
CLN Concentration* 
(ng mL
-1
) 
Reaction time (min) 
1.53 50000 0 
0.95 58.27 5 
0.77 40.39 10 
1.44 26.10 15 
1.36 15.62 20 
0.49 8.520 25 
1.72 x 10
-4
 0.001 30 
Table S2. 
13
C-NMR spectral data of CLN and 3- demethyl CLN. 
3- demethyl CLN  CLN Carbon 
153.57  153.57 1 
141.94  141.74 2 
151.90  151.25 3 
109.09  107.39 4 
29.92  29.92 5 
36.62  36.62 6 
52.60  52.60 7 
130.56  130.56 8 
179.54  179.54 9 
164.07  164.07 10 
112.72  112.72 11 
135.47  135.47 12 
169.90  169.90 13 
22.90  22.90 14 
125.69  125.69 1a 
134.21  134.21 4a 
152.09  152.06 7a 
136.76  136.76 12a 
61.42  61.41 1-OCH3 
61.58  61.58 2-OCH3 
------  56.42 3-OCH3 
56.10  56.16 10-OCH3 
- Chemical shift values are expressed in ppm. 
 
 
 
Figure captions 
Figure S1. Degradation of CLN in a Carousel 6 Plus Reaction Station™ set. 
Figure S2. Fractions eluted using the fractional column chromatography (A) and the 
collected product from CLN degradation (B). 
Figure S3. Absorption spectrum of standard solution of CLN (20.0 g/mL prepared 
in double distilled water). 
Figure S4. Calibration of H2O2 by HPLC/UV detection at 248 nm using different 
concentration of H2O2 (50- 400 ppm) prepared in acidic water (pH 3.0). 
 
